Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Haloperidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 15/20 | 0.80 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.80 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.80 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.80 |
| ▸ | HTR1A | P08908 | 3/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.80 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.80 |
| ▸ | HRH1 | P35367 | 3/20 | 0.80 |
| ▸ | HTR2C | P28335 | 2/20 | 0.80 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Haloperidol SCHEMBL19463557 | 1.00 | DRD2 (0.80) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL4177109 | 1.00 | DRD2 (0.80) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL28595609 | 0.99 | DRD2 (0.78) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL10392879 | 0.95 | DRD2 (0.72) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL10392880 | 0.95 | DRD2 (0.72) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL5452448 | 0.95 | DRD2 (0.72) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Bromperidol SCHEMBL27681710 | 0.91 | DRD2 (0.80) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Trifluperidol SCHEMBL4122414 | 0.90 | ABCB11 (0.73) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL9507217 | 0.89 | DRD2 (0.92) | DRD2ADRA1ADRD3DRD4HTR1A | |
| Haloperidol SCHEMBL5070670 | 0.89 | DRD2 (1.00) | DRD2ADRA1ADRD3DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3343 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387622-B1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | UNIV VALENCIA (ES) | 2025-05-28 | — | — | EP | claimed |
| US-20240390356-A1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Universitá degli Studi di Torino (IT) | 2024-11-28 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4387622-A1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Universitat de València (ES) | 2024-06-26 | — | — | EP | claimed |
| EP-3383371-B1 | PHARMACEUTICAL FORMULATION | AVECHO BIOTECHNOLOGY LTD (AU) | 2024-05-01 | — | — | EP | claimed |
| US-20230218623-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-07-13 | — | — | US | claimed |
| WO-2023118164-A1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | UNIVERSITAT DE VALÈNCIA (ES) | 2023-06-29 | — | — | WO | claimed |
| EP-4197536-A1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Universitat de València (ES) | 2023-06-21 | — | — | EP | claimed |
| CN-110325193-B | Novel medical use of compound III | 勃林格殷格翰国际有限公司 | 2023-05-05 | — | — | CN | claimed |
| EP-4146656-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | Syneurx International (Taiwan) Corp. (TW) | 2023-03-15 | — | — | EP | claimed |
| WO-1999052519-A2 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 1999-10-21 | — | — | WO | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1996001631-A1 | NOVEL COMBINATION PRODUCT COMPRISING CAPRIPRAMINE AND A NEUROLEPTIC | PIERRE FABRE MEDICAMENT (FR) | 1996-01-25 | — | — | WO | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0580776-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| US-5231099-A | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-07-27 | — | — | US | claimed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | claimed |